Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

SYDNEY, March 12, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2^nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.

About Novogen Limited
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's website, www.novogen.com.  

For Further Information Contact:

Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO

SOURCE Novogen Limited